News articles about Depomed (NASDAQ:DEPO) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Depomed earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 44.597108180957 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
DEPO has been the subject of a number of recent research reports. Mizuho upgraded Depomed from a “neutral” rating to a “buy” rating and set a $9.00 target price for the company in a research report on Tuesday, December 5th. Morgan Stanley upgraded Depomed from an “underweight” rating to an “equal weight” rating in a research report on Thursday, November 9th. Piper Jaffray Companies restated a “hold” rating and issued a $9.00 target price on shares of Depomed in a research report on Sunday, September 10th. Royal Bank of Canada set a $8.00 target price on Depomed and gave the stock a “hold” rating in a research report on Friday, October 27th. Finally, BidaskClub upgraded Depomed from a “sell” rating to a “hold” rating in a research report on Wednesday, December 6th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $11.64.
Shares of Depomed (NASDAQ:DEPO) traded down $0.09 during trading on Friday, reaching $8.58. The company’s stock had a trading volume of 629,849 shares, compared to its average volume of 1,875,251. The company has a quick ratio of 0.79, a current ratio of 0.83 and a debt-to-equity ratio of 2.90. The stock has a market cap of $546.33, a PE ratio of -4.69 and a beta of 1.30. Depomed has a 1-year low of $4.31 and a 1-year high of $21.38.
In related news, insider Arthur J. Higgins purchased 75,000 shares of the firm’s stock in a transaction on Thursday, December 14th. The shares were acquired at an average cost of $8.16 per share, with a total value of $612,000.00. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 2.59% of the stock is owned by insiders.
COPYRIGHT VIOLATION NOTICE: “Depomed (DEPO) Given Media Impact Rating of 0.12” was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.com-unik.info/2017/12/23/depomed-depo-given-media-impact-rating-of-0-12.html.
Depomed, Inc is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl).
Receive News & Ratings for Depomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed and related companies with MarketBeat.com's FREE daily email newsletter.